Oncimmune Holdings PLC (AIM:ONC) said it has landed two new contracts for its ImmunoINSIGHTS services.
The first contract is with a US clinical-stage biopharmaceutical company developing immunotherapies for cancer natural killer cell and CAR-NK cell products.
Oncimmune will use its biomarker discovery platform, SeroTag, to identify autoantibodies that can be predictive of patient clinical response, and potential resistance.
The second deal is again with a US biopharma, that is also active in the field of immuno-oncology.
This project will profile the autoantibodies in patients treated with a virus-like particle that stimulates anti-tumour T cells with the aim of discovering and demonstrating how the immune system is affected by the therapy.
“Unlocking the utility of the ImmunoINSIGHTS platform in these cutting-edge therapies promises to substantially improve clinical outcomes for cancer patients," said Oncimmune chief executive, Dr Adam Hill.
No financial details were given.
There has been a flurry of similar contracts for Oncimmune’s ImmunoINSIGHTS services that underline its commercial potential.